Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other Operating Expenses (2022 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Other Operating Expenses for 3 consecutive years, with $4.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Operating Expenses changed N/A year-over-year to $4.7 million, compared with a TTM value of $16.9 million through Sep 2025, changed N/A, and an annual FY2024 reading of $12.2 million, changed N/A over the prior year.
  • Other Operating Expenses was $4.7 million for Q3 2025 at Barinthus Biotherapeutics, down from $12.2 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $19.4 million in Q4 2022 and bottomed at -$10.2 million in Q3 2022.
  • Average Other Operating Expenses over 3 years is $4.0 million, with a median of $4.7 million recorded in 2025.